Vascular risk: Diabetes

Vascular Medicine

Volumn 9, Issue 4, 2004, Pages 307-310

  Collinson, Deborah J ^a   Rea, Rustam ^a   Donnelly, Richard ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ANTIDIABETIC AGENT; CILOSTAZOL; DIACYLGLYCEROL; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTOXIFYLLINE; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C BETA; SIMVASTATIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLLATERAL CIRCULATION; DIABETES CONTROL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LEG AMPUTATION; LIMB ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 13444301422     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm550xx     Document Type: Article

References (33)

1. Uusitupa M, Niskanen L, Siitonen O, Pyorala K. 5-year incidence of atherosclerotic vascular disease in relation to gender, risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic individuals. Circulation 1990; 82: 27-36.
2. Fowkes FG. Epidemiological research on peripheral vascular disease. J Clin Epidemiol 2001; 54: 863-68.
3. Da Silva A, Desgranges P, Holdsworth J et al. The management and outcome of critical limb ischaemia in diabetic patients: results of a national survey. Audit committee of the vascular surgical society of Great Britain and Ireland. Diabet Med 1996; 13: 726-28.
4. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24: 1433-37.
5. Mehler P, Jeffers B, Estacio, R, Schrier R. Associations of hypertension and complications in NIDDM. Am J Hypertens 1997; 10 152-61.
6. Beks P, Mackaay A, de Neeling J, de Vries H, Bouter L, Heine M. Peripheral aterial disease in relation to glycaemic level in an elderly caucasian population: the Hoorn study. Diabetologia 1995; 38: 86-96.
7. Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 2000; 148: 159-69.
8. Adler A, Stevens R, Neil A, Stratton I, Boulton A, Holman R. UKPDS 59: hyperglycaemia and other potentially modifiable risk factors for peripheral arterial disease in type 2 diabetes. Diabetes Care 2002; 25: 894-99.
9. Price J, Lee A, Fowkes F. Hyperinsulinaemia: a risk factor for peripheral arterial disease in the non-diabetic population. J Cardiovasc Risk 1996; 3: 501-505.
10. Matsumoto K, Miyake S, Yano M et al. Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Diabetes Care 1997; 20: 1738-43.
11. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
12. Schmidt A, Yan S, Wautier J, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
13. Idlis I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001; 44: 659-73.
14. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-β inhibitor. Science 1996; 272: 728-31.
15. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase C-β prevents impaired endothelium-dependent vasodilation caused by hyperglycaemia. Circ Res 2002; 90: 107-11.
16. Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NADPH oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-45.
17. Creager MA, Luscher TF. Diabetes and vascular disease. Pathophysiology, clinical consequences and medical therapy: Part 1. Circulation 2003; 108: 1527-32.
18. Kuboki K, Jiang ZY, Takahara N et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000; 101: 676-81.
19. Laakso M, Edelman SV, Brechtel G et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism of insulin resistance. J Clin Invest 1990; 85: 1844-52.
20. Mather K, Laakso M, Edelman S et al. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 2000; 279: E1264-70.
21. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344-50.
22. DCCT Study Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
25. MacGregor A, Price J, Hau C, Lee A, Carson M, Fowkes F. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study. Diabetes Care 1999; 22: 453-458.
26. Adler A, Stratton I, Neil A et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412-19.
27. Mehler PS, Coll JR, Estacio, R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-56.
28. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
29. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-28.
30. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischaemia model. Circulation 2001; 104 2344-50.
31. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B. Rescue of diabetes related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-63.
32. Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Cesarone MR, Incandela L. Intermittent claudication in diabetics: treatment with exercise and pentoxifylline - a 6-month, controlled, randomized trial. Angiology 2002; 53 (suppl 1): S39-43.
33. Hittel N, Donnelly R. Treating peripheral arterial disease in patients with diabetes. Diabetes Obes Metab 2002; 4 (suppl 2): S26-31.